NEWSROOM | Galderma

Acne Awareness Month 2024: understanding acne scarring

Galderma launches Restylane® Volyme™ in China – one of the world’s fastest growing aesthetics markets

Galderma receives filing acceptances for nemolizumab in prurigo nodularis and atopic dermatitis in four additional countries

Galderma delivers a strong start to the year with record net sales of over 1 billion USD for the first quarter and 12.4% year-on-year growth

An organization built on uniqueness

Celebrating Galderma’s listing on the SIX Swiss Exchange

Galderma announces full exercise of over-allotment option

Galderma prices IPO at CHF 53 per share and will start trading on the SIX Swiss Exchange tomorrow

AMWC 2024: Galderma to share new data from its leading injectable aesthetic portfolio

AMWC 2024: Scientific presentations supported by Galderma

Galderma launches IPO on the SIX Swiss Exchange and sets price range

Dr. Flor A. Mayoral: A story of creativity, passion and dermatological innovation with Galderma